You just read:

FDA Accepts CSL Behring's Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication

News provided by

CSL Behring

Jul 19, 2017, 09:30 ET